Q: This morning, Opsens received a takeover offer from Haemonetics. Do you think there's any potential for other bidders to offer more than the current $2.90 cash offer?
Many thanks.
Many thanks.
5i Research Answer:
The $2.90 bid is all cash, and a 'decent' premium. One could argue OPS could have gotten a bit more, but we believe the company 'shopped' itself and market conditions likely prevented a higher premium. But it is a 61% premium to its average recent price and we would not expect another offer. Still, the chances of such would still be above 0%, so we would still see it as a HOLD today. It is trading fairly close to the offer price, implying some shareholders may want a bit more.